Author

Daniel Muñoz‐Espín

University of CambridgeORCID 0000-0002-0550-9514Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Anna C. ObenaufiD· 1 shared Anna Dyas· 1 shared Cissy YongiD· 1 shared Grant Duncan StewartiD· 1 shared Hui‐Ling OuiD· 1 shared James E. KorkolaiD· 1 shared Jarno DrostiD· 1 shared Jianfeng GeiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anna C. ObenaufORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCell Death and DiseasePeer-reviewedOct 5, 2026

Identification of senescence-associated drivers of tumour growth and progression using a novel microarray platform

Hui‐Ling Ou, Reuben J. Hoffmann, Rebecca Smith…·James E. Korkola

This study identifies SASP factors that drive tumorigenesis in breast and lung cancer cells using a microarray platform and validates their role in growth and survival.

DOI 10.1038/s41419-026-09309-5

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyEMBO Molecular MedicinePeer-reviewedDec 19, 2025

Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities

Jianfeng Ge, Shoko Hirosue, Leticia Castillon…·Sakari Vanharanta

This study identifies HIF1A as a key inhibitor of VHL null cell fitness and shows that combined VHL/HIF1A inactivation can confer resistance to PROTAC-based therapies.

3 citations

humangenetic perturbation / CRISPR

𝕏 PostBluesky